Tags

Type your tag names separated by a space and hit enter

Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.

Abstract

It is widely accepted that non-endogenous compounds that target CB(1) and/or CB(2) receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB(1)/CB(2) receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB(2)-selective agonists, peripherally restricted CB(1)/CB(2) receptor agonists and CB(1)/CB(2) antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB(1) and CB(2) receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB(1), non- CB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB(1) and/or CB(2) receptors.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    Institute of Medical Sciences, University of Aberdeen, Foresterhill, Scotland, UK. rgp@abdn.ac.uk

    Source

    Current medicinal chemistry 17:14 2010 pg 1360-81

    MeSH

    Cannabinoid Receptor Agonists
    Cannabinoid Receptor Antagonists
    Dronabinol
    Ion Channels
    Ligands
    Piperidines
    Pyrazoles
    Receptors, Cannabinoid
    Receptors, Cytoplasmic and Nuclear
    Receptors, G-Protein-Coupled
    Rimonabant

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    20166927

    Citation

    Pertwee, R G.. "Receptors and Channels Targeted By Synthetic Cannabinoid Receptor Agonists and Antagonists." Current Medicinal Chemistry, vol. 17, no. 14, 2010, pp. 1360-81.
    Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010;17(14):1360-81.
    Pertwee, R. G. (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Current Medicinal Chemistry, 17(14), pp. 1360-81.
    Pertwee RG. Receptors and Channels Targeted By Synthetic Cannabinoid Receptor Agonists and Antagonists. Curr Med Chem. 2010;17(14):1360-81. PubMed PMID: 20166927.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. A1 - Pertwee,R G, PY - 2009/12/01/received PY - 2010/02/18/accepted PY - 2010/2/20/entrez PY - 2010/2/20/pubmed PY - 2010/7/29/medline SP - 1360 EP - 81 JF - Current medicinal chemistry JO - Curr. Med. Chem. VL - 17 IS - 14 N2 - It is widely accepted that non-endogenous compounds that target CB(1) and/or CB(2) receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB(1)/CB(2) receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB(2)-selective agonists, peripherally restricted CB(1)/CB(2) receptor agonists and CB(1)/CB(2) antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB(1) and CB(2) receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB(1), non- CB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB(1) and/or CB(2) receptors. SN - 1875-533X UR - https://www.unboundmedicine.com/medline/citation/20166927/Receptors_and_channels_targeted_by_synthetic_cannabinoid_receptor_agonists_and_antagonists_ L2 - http://www.eurekaselect.com/71421/article DB - PRIME DP - Unbound Medicine ER -